Asahi Kasei Expands Global Pharma Reach with €780 Million Buy of Aicuris

Japanese industrial giant Asahi Kasei has agreed to acquire German biopharmaceutical firm Aicuris Anti-infective Cures AG for about €780 million (roughly $919 million), a deal aimed at strengthening its specialty pharmaceutical platform and accelerating growth in treatments for severe infectious diseases.

Under the terms of the definitive agreement, Asahi Kasei will purchase all issued shares of Aicuris, with the acquisition expected to close in the first quarter of fiscal 2026, subject to customary regulatory approvals and closing conditions. The transaction marks a significant expansion of Asahi Kasei’s healthcare portfolio, particularly in areas that intersect with its existing transplant and nephrology businesses.

Aicuris, a specialist focused on antiviral therapies for immunocompromised patients, brings three important assets into Asahi Kasei’s portfolio. The first, Prevymis® (letermovir), is a marketed cytomegalovirus drug licensed to Merck & Co., Inc. that generates royalty revenue and is used to prevent infection in transplant recipients.

The second asset, pritelivir, is an oral helicase-primase inhibitor being developed to treat herpes simplex virus (HSV) infections in immunocompromised patients. This candidate has completed Phase III clinical trials, with U.S. FDA approval targeted for 2026, offering a potential near-term commercial opportunity.

The third compound, AIC468, is in earlier development as an antisense oligonucleotide aimed at treating BK virus (BKV) infections in kidney transplant recipients. The Phase I program has already been completed, and commercialization is targeted around 2030, aligning with long-term growth ambitions.

Asahi Kasei said the acquisition is consistent with its strategy to build a focused and sustainable specialty pharmaceutical platform that serves medically complex patient groups, including those with autoimmune diseases, kidney disease, and infectious complications arising from organ transplants. The company expects the deal to positively contribute to operating income after amortization of goodwill and intangible assets beginning in fiscal 2028.

Ken Shinomiya, Head of Asahi Kasei’s Healthcare Sector, emphasized that the strategic alignment of Aicuris’s pipeline with Asahi Kasei’s existing operations will enhance the company’s global specialty pharma leadership and support ambitious financial targets—namely achieving net pharmaceutical sales of ¥300 billion with at least a 15 % operating margin by fiscal 2030.

Industry observers note that Aicuris’s expertise in antiviral drug development fits well with Asahi Kasei’s broader push into high-growth, high-value therapeutic areas. In recent years, the Japanese firm has been transforming its portfolio, prioritizing healthcare innovations alongside its traditional industrial businesses.

The acquisition not only strengthens Asahi Kasei’s R&D pipeline but also leverages its established commercial infrastructure in transplant and nephrology markets to enhance uptake of Aicuris’s products and accelerate global market access.

Overall, the deal underlines a broader trend of consolidation and strategic investment in the biotech sector as pharmaceutical companies seek to respond to evolving medical challenges, including severe infections in vulnerable populations.